Ahmed Nader
Overview
Explore the profile of Ahmed Nader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han K, Youssef A, Magee M, Hood S, Tracey H, Kwoh J, et al.
Clin Pharmacol Drug Dev
. 2025 Feb;
PMID: 39950613
Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection. Given the importance of coadministration of bepirovirsen and standard-of-care nucleos(t)ide analogs (NAs),...
2.
Youssef A, Ismail M, Han K, Magee M, Nader A
Infect Dis Ther
. 2024 Oct;
13(12):2663.
PMID: 39460893
No abstract available.
3.
Noormohamed N, Lukic T, Marbury T, Lawitz E, Prescott H, Magee M, et al.
Clin Pharmacol Drug Dev
. 2024 Sep;
13(10):1088-1097.
PMID: 39268699
Bepirovirsen is a developmental antisense oligonucleotide (ASO) for treatment of chronic hepatitis B virus infection. No pharmacokinetic (PK) studies comparing participants with hepatic impairment (HI) and healthy participants (HPs) have...
4.
Youssef A, Ismail M, Han K, Magee M, Nader A
Infect Dis Ther
. 2024 May;
13(7):1515-1530.
PMID: 38796564
Introduction: Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therapy. Understanding the impact that clinical characteristics may have on bepirovirsen exposure is important...
5.
Boonyaratanakornkit J, Wang Q, Nader A, Kimball L, Stevens-Ayers T, Levkova M, et al.
J Infect Dis
. 2024 May;
230(3):670-679.
PMID: 38743457
Background: Monoclonal antibodies (mAbs) are utilized broadly to treat cancer and infectious diseases, and mAb exposure (serum concentration over time) is one predictor of overall treatment efficacy. Herein, we present...
6.
Fleischmann R, Friedman A, Drescher E, Singhal A, Cortes-Maisonet G, Doan T, et al.
Lancet Rheumatol
. 2024 Jan;
4(6):e395-e406.
PMID: 38293957
Background: ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases....
7.
Nader A, Alexander E, Brintziki D, Haggag A, Harrison S, Hawes I, et al.
Clin Pharmacokinet
. 2023 Nov;
63(1):57-68.
PMID: 37955825
Background And Objective: Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan for treatment of SARS-CoV-2 infection in adults...
8.
Shapiro A, Sarkis E, Acloque J, Free A, Gonzalez-Rojas Y, Hussain R, et al.
Open Forum Infect Dis
. 2023 Aug;
10(8):ofad354.
PMID: 37577112
Background: Convenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) administration for...
9.
Ismail M, Doelger E, Eckert D, Irvine A, Chu A, Teixeira H, et al.
Br J Clin Pharmacol
. 2023 May;
89(10):3139-3151.
PMID: 37232215
Aims: First, population pharmacokinetic analyses were used to characterize upadacitinib pharmacokinetics in adolescent and adult participants with atopic dermatitis (AD) and to identify patient covariates that may impact upadacitinib pharmacokinetics....
10.
Sager J, El-Zailik A, Passarell J, Roepcke S, Li X, Aldinger M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Mar;
12(6):853-864.
PMID: 36922886
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non-hospitalized high-risk patients with mild to moderate coronavirus disease 2019 following...